HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US

被引:30
|
作者
Liu, Guodong [1 ]
Kong, Lan [1 ]
Du, Ping [1 ,2 ]
机构
[1] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA USA
[2] Penn State Univ, Coll Med, Dept Med, Hershey, PA USA
来源
PAPILLOMAVIRUS RESEARCH | 2016年 / 2卷
关键词
HPV vaccine completion; HPV vaccine dose adherence; Commercially insured females;
D O I
10.1016/j.pvr.2015.10.001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Although HPV vaccination has been recommended for use in girls and young women since 2007, HPV vaccine uptake is low in the US. Methods: We conducted a retrospective cohort study using the 2008-2011 MarketScan data to examine HPV vaccine completion and dose adherence among commercially insured females aged 9-26 years. We performed multivariable logistic regression models to examine factors related to HPV vaccine completion and HPV vaccine dose adherence. Results: Among 378,484 females aged 9-26 years who initiated HPV vaccination, only 29.4% completed HPV vaccination. Compared with females receiving vaccines from primary care providers, those receiving vaccines from OB/GYN providers were more likely to complete the vaccine series. Age at HPV vaccine initiation, health insurance plan, seasonal pattern, and flu vaccination were also significantly associated with vaccine completion. Among 111,286 females who completed HPV vaccination, 62.4% received all doses within 30 days of the recommended schedules. Similar factors relating to HPV vaccine completion were consistently associated with HPV vaccine dose adherence. However, younger age ( <22 years) and receipt of flu vaccine were negatively related to HPV vaccine dose adherence. Conclusions: Intervention programs to improve HPV vaccine reminding system and reduce logistic barriers for both physicians and patients are warranted. (C) 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1 / 8
页数:8
相关论文
共 29 条
  • [21] Factors associated with HPV vaccine initiation among males aged 11-26 years attending outpatient clinics in the Baltimore Metro Area during 2012-2013
    Clarke, Megan
    Phelan-Emrick, Darcy F.
    Coutinho, Francesca
    Chou, Betty
    Joshu, Corinne E.
    CANCER RESEARCH, 2015, 75
  • [22] Coverage with the First Dose of Human Papillomavirus Vaccination among Females Aged 9-50 Years in Shenzhen, China: A Surveillance Based on Administrative Health Records in 2023
    Lin, Zian
    Liang, Xue
    Su, Lixian
    Peng, Weijun
    Chen, Hongbiao
    Fang, Yuan
    Chen, Siyu
    Yang, Weikang
    Chen, Wensheng
    Zhang, Lijun
    Wang, Zixin
    VACCINES, 2024, 12 (01)
  • [23] Potential impact of HPV vaccine on incidence of high-grade vulvar, vaginal, and anal precancers among females and males aged 15 to 39 years, United States 2000 to 2017.
    Saraiya, Mona
    Senkomago, Virginia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Influences of HPV disease perceptions, vaccine accessibility, and information exposure on social media on HPV vaccination uptake among 11,678 mothers with daughters aged 9-17 years in China: a cross-sectional study
    Lin, Zian
    Chen, Siyu
    Su, Lixian
    Liao, Yuxue
    Chen, Hongbiao
    Hu, Zhiqing
    Chen, Zhuolin
    Fang, Yuan
    Liang, Xue
    Chen, Jianan
    Luo, Biyun
    Wu, Chuanan
    Wang, Zixin
    BMC MEDICINE, 2024, 22 (01):
  • [25] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial
    Leung, Ting Fan
    Liu, Anthony Pak-Yin
    Lim, Fong Seng
    Thollot, Franck
    Oh, Helen May Lin
    Lee, Bee Wah
    Rombo, Lars
    Tan, Ngiap Chuan
    Rouzier, Roman
    Friel, Damien
    De Muynck, Benoit
    De Simoni, Stephanie
    Suryakiran, Pemmaraju
    Hezareh, Marjan
    Folschweiller, Nicolas
    Thomas, Florence
    Struyf, Frank
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (07) : 1689 - 1702
  • [26] Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged ≥ 12 years, United States, August 2021-October 2022
    Meng, Lu
    Harris, Latreace
    Shaw, Lauren
    Lymon, Hoody
    Reses, Hannah
    Bell, Jeneita
    Lu, Peng -Jun
    Gibbs-Scharf, Lynn
    Chorba, Terence
    VACCINE, 2024, 42 (09) : 2122 - 2126
  • [27] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial
    Leung, Ting Fan
    Liu, Anthony Pak-Yin
    Lim, Fong Seng
    Thollot, Franck
    Oh, Helen May Lin
    Lee, Bee Wah
    Rombo, Lars
    Tan, Ngiap Chuan
    Rouzier, Roman
    De Simoni, Stephanie
    Suryakiran, Pemmaraju
    Hezareh, Marjan
    Thomas, Florence
    Folschweiller, Nicolas
    Struyf, Frank
    VACCINE, 2018, 36 (01) : 98 - 106
  • [28] Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis
    Levin, Myron J.
    Divino, Victoria
    Shah, Drishti
    DeKoven, Mitch
    Mould-Quevedo, Joaquin
    Pelton, Stephen, I
    Postma, Maarten J.
    VACCINES, 2021, 9 (10)
  • [29] Two-dose seasonal influenza vaccine coverage and timeliness among children aged 6months through 3years: An evidence from the 2010-11 to the 2014-15 seasons in Zhejiang province, east China
    Hu, Yu
    Chen, Yaping
    Zhang, Bing
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (01) : 75 - 80